There is a global epidemic of myopia (aka short-sightedness) and associated eye disease. Myopia control is a new and rapidly evolving therapeutic area designed to slow down the spread of the condition and reduce the risk of vision loss and blindness (myopia currently affects 2 billion people globally, and is predicted to rise to 5 billion by 2050, with 1 billion at risk of blindness). With new treatments emerging, new research to interpret and new clinical challenges to address, clinicians are struggling to get to grips with the demands of myopia control.

Ocumetra delivers personalised myopia care solutions and vital decision support to practitioners in this rapidly changing field of clinical practice. Our pioneering technology, which we have called the Refractogram, makes advanced myopia treatment accessible to all.

Comprising a unique portfolio of clinically relevant features including interactive ocular growth charts, myopia treatment efficacy analytics and other clinical decision support tools, our Refractogram is the essential technology for evidence-based myopia control. The interactive growth charts allow clinicians to identify patients most in need of treatment, while our comprehensive analytics and graphical displays allow treatment decisions to be optimised for every patient and treatment benefits demonstrated to every patient. With the Refractogram, Ocumetra provides the answers clinicians need to deliver personalised, adaptive eye care to every myopia patient.

Ocumetra's ambition is to make ocular growth analysis a core component of clinical care for myopia, to make the Ocumetra brand synonymous with comprehensive myopia care and to establish our Refractogram as the essential clinical tool for every ophthalmic practitioner managing myopia. Evidence based treatment guided by our groundbreaking analytic and graphical tools can enable clinicians to prevent avoidable vision loss and blindness among the ever increasing number of patients developing progressive myopia.